Literature DB >> 15233646

Antibody response to the patient's own Haemophilus influenzae isolate can support the aetiology in lower respiratory tract infections.

Kristoffer Strålin1, Hans Holmberg, Per Olcén.   

Abstract

In order to understand the clinical importance of Haemophilus influenzae isolated from sputum samples, an indirect immunofluorescence (IF) assay was developed, using the patient's own isolate as the antigen. The method was tested on samples from six patients with lower respiratory tract infection (LRTI) and H. influenzae isolated from blood (n=2), sputum (n=3) or both (n=1), and on two healthy adults with H. influenzae isolated from the nasopharynx. Between acute and convalescent sera, a four-fold IgG antibody increase was achieved in five of six LRTI patients, including the three blood culture-positive patients. One LRTI patient and the two asymptomatic carriers showed stable antibody levels against their own isolate. Although small, the study indicates that indirect IF can be a promising tool for determining whether a H. influenzae strain represents the probable cause of infection or just a strain colonising the airways. More extensive studies should be performed in order to establish the usefulness of the assay.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15233646     DOI: 10.1111/j.1600-0463.2004.apm11204-0511.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  2 in total

1.  Etiologic diagnosis of adult bacterial pneumonia by culture and PCR applied to respiratory tract samples.

Authors:  Kristoffer Strålin; Eva Törnqvist; Margit Staum Kaltoft; Per Olcén; Hans Holmberg
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

2.  High HMGB1 levels in sputum are related to pneumococcal bacteraemia but not to disease severity in community-acquired pneumonia.

Authors:  Helena Alpkvist; Simon Athlin; Paula Mölling; Anna Norrby-Teglund; Kristoffer Strålin
Journal:  Sci Rep       Date:  2018-09-07       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.